Immix Biopharma
IMMX
31 hedge funds and large institutions have $5.78M invested in Immix Biopharma in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
35% more funds holding
Funds holding: 23 → 31 (+8)
23% more capital invested
Capital invested by funds: $4.68M → $5.78M (+$1.1M)
1.48% more ownership
Funds ownership: 8.11% → 9.59% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$215K |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$170K |
| 3 |
State Street
Boston,
Massachusetts
|
+$134K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$132K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$96.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$37K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$28.9K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$23K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$11K |
| 5 |
Morgan Stanley
New York
|
-$10.2K |
IMMX Hedge Fund Activity: Q3 2025 in Review
31 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2025, worth a combined $5.78M — up 23% from $4.68M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IMMX positions and 4 closed out — a net gain of 8 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $215K. The largest seller was Virtu Financial, exiting entirely with an estimated $37K sold.
- 31 institutional investors held Immix Biopharma (IMMX) as of Q3 2025, up from 23 in Q2 2025.
- Funds reported $5.78M of Immix Biopharma stock for Q3 2025, up 23% quarter-over-quarter.
- 12 funds opened new Immix Biopharma positions in Q3 2025 and 4 closed out, a net change of +8 holders.
- The largest Immix Biopharma buyer in Q3 2025 was Citadel Advisors, an estimated $215K added.
- The largest Immix Biopharma seller in Q3 2025 was Virtu Financial, an estimated $37K sold.
Based on aggregated 13F filings for Q3 2025.